Antev is a biotechnology company with a focus on urology. The company’s primary products are based upon the GnRH Antagonist Teverelix molecule and platform technology, and the lead indication is for benign prostatic hyperplasia and acute urinary retention.

The Teverelix indications are in Phase II and entering Phase III clinical development, and the Company is preparing to open Investigational New Drugs with the US Food & Drug Agency following work to date under the European Medicines Agency.